TSHA Q4 2020 Earnings — Taysha Gene Therapies, Inc. Revenue & Financial Results | Market Cap Arena

TSHATaysha Gene Therapies, Inc.

$1B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$18M

Net Income

-$18M

EPS (Diluted)

$-0.49

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$26M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$259M

Total Liabilities

$8M

Stockholders' Equity

$251M

Cash & Equivalents

$251M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$18M	-$1M	-1547.3%
Net Income	-$18M	-$1M	-1542.9%